Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors, including hepatocellular carcinoma, gastric cancer, and squamous cell carcinoma of the lung. The company is based in Boston, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: adicetbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2024 | $7.00 | Buy | Guggenheim |
| 9/11/2024 | Buy → Neutral | H.C. Wainwright | |
| 6/27/2023 | Buy → Neutral | Guggenheim | |
| 6/27/2023 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 6/1/2023 | $20.00 → $6.00 | Overweight → Neutral | JP Morgan |
| 9/21/2022 | $23.00 | Overweight | JP Morgan |
| 3/31/2022 | $28.00 | Outperform | SMBC Nikko |
| 3/8/2022 | $30.00 | Buy | Truist Securities |
| 3/4/2022 | $27.00 | Buy | Jefferies |
| 12/6/2021 | $22.00 → $32.00 | Buy | Guggenheim |
First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials Preliminary Phase 1 clinical data expected in the first half of 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). "Solid tumors represent one of the highest unmet medical needs in oncology and have yet to benefit from the breakthroughs observed with CAR T cell therapies in hematologic mal
Enrollment underway for lupus nephritis (LN) patients Preliminary clinical data in LN anticipated in 1H25 Initiation of patient enrollment in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) expected in 1Q25; patient enrollment in anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) expected in 2H25 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in au
ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephritis (LN) anticipated in 1H25 Strong balance sheet with $202.1 million in cash, cash equivalents and short-term investments as of September 30, 2024 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2024. "Our commitment to delivering best-in-class gamma delta 1 T cell therapies for patients battling autoimmune diseases and cancer
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C. Details of the oral presentation are as follows: Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications Session Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II Abstract Number: 1866169 Presenting Author: Monica Moreno, Ph.D. Date and Tim
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in three upcoming investor conferences in November. Details of the events are as follows: Truist Securities BioPharma Symposium, November 7, 2024, New York, NY Members of management will be available for 1x1 meetings on November 7, 2024 Guggenheim Securities Healthcare Innovation Conference, November 11-13, 2024, Boston, MA Chen Schor, President and Chief Executive Officer, will participate in a fireside chat on November 12, 2024 at 3:00 p.m. ET Jefferie
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2024. Three individuals were hired by Adicet in October 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 59,800 shares of Adicet's common stock with an exercise price of $1.28 per share, the closing price of Adicet's common stock as reported by Nasdaq on October 31, 2024. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the rema
ADI-001 clinical development program now addresses six autoimmune diseases Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be initiated in the first quarter of 2025 Company plans to report initial clinical data from Phase 1 study in multiple autoimmune diseases in the first half of 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amendment to the Company's Investigational New Drug (IND) application to evaluate ADI-001 in idiopa
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on September 30, 2024. Four individuals were hired by Adicet in September 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 33,600 shares of Adicet's common stock with an exercise price of $1.44 per share, the closing price of Adicet's common stock as reported by Nasdaq on September 30, 2024. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, taking place October 16 – 17, 2024, in Philadelphia, PA. Details of the oral presentation are as follows: Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology Indications Session Name: Novel Targets and Effector Cells Abstract Number: 8 Presenting Author:
Activated clinical sites for Phase 1 trial of ADI-001 in autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) Enrollment open for patients with LN; enrollment in SLE, SSC, and AAV expected to open in the fourth quarter of 2024 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. "The favorable safety profile, cellula
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
10-Q - Adicet Bio, Inc. (0001720580) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
8-K - Adicet Bio, Inc. (0001720580) (Filer)
10-Q - Adicet Bio, Inc. (0001720580) (Filer)
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
HC Wainwright & Co. analyst Edward White reiterates Adicet Bio (NASDAQ:ACET) with a Buy and maintains $10 price target.
Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.39) by 10.26 percent.
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
3 - Adicet Bio, Inc. (0001720580) (Issuer)
4 - Adicet Bio, Inc. (0001720580) (Issuer)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13D/A - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G - Adicet Bio, Inc. (0001720580) (Subject)
SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)
Guggenheim resumed coverage of Adicet Bio with a rating of Buy and set a new price target of $7.00
H.C. Wainwright downgraded Adicet Bio from Buy to Neutral
Guggenheim downgraded Adicet Bio from Buy to Neutral
JMP Securities downgraded Adicet Bio from Mkt Outperform to Mkt Perform
JP Morgan downgraded Adicet Bio from Overweight to Neutral and set a new price target of $6.00 from $20.00 previously
JP Morgan initiated coverage of Adicet Bio with a rating of Overweight and set a new price target of $23.00
SMBC Nikko initiated coverage of Adicet Bio with a rating of Outperform and set a new price target of $28.00
Truist Securities initiated coverage of Adicet Bio with a rating of Buy and set a new price target of $30.00
Jefferies initiated coverage of Adicet Bio with a rating of Buy and set a new price target of $27.00
Guggenheim reiterated coverage of Adicet Bio with a rating of Buy and set a new price target of $32.00 from $22.00 previously
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. "We are pleased to welcome Dr. Klickstein to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Klickstein's expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform as a former executive at Adicet will be very valuable as we progress our autoimmune programs across multiple indications. I loo
Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application (IND) for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205.5 million in cash and cash equivalents as of June 30, 2023 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2023.
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Katie Peng to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711946213/en/Katie Peng, Board of Directors, Adicet Bio, Inc. (Photo: Business Wire) "We are delighted to welcome Katie to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Her proven success as a commercial leader in both the U.S. and globally will be particularly valuable to Adicet as we advance ADI-001 and our pi
Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL); Next data update expected in Q2 2023 Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting and Adicet's R&D Pipeline Event Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2022. "I
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the appointment of Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer. Dr. Boman will spearhead Adicet's regulatory strategy to further advance existing and new pipeline opportunities for the Company's gamma delta T cell platform. "We are incredibly excited to welcome Nancy to the Adicet team," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Her vast experience in successfully filing marketing applications for more than 15 products, including in hematologic malignancies, such
MENLO PARK, Calif. and BOSTON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (NASDAQ:ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors. "Dr. Kauffman's appointment brings a wealth of expertise to our board and will be invaluable as we advance the development of our pipeline of next-generation off-the-shelf, gamma-delta CAR-T therapies," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Kauffman is an industry veteran with considerable experience in oncology drug development
MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (NASDAQ:ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Blake Aftab, Ph.D., as Vice President of Research. Dr. Aftab will lead Adicet's research group and will further develop existing and new opportunities for the Company's gamma delta T cell platform. "We are very excited to have Blake join Adicet, and lead our research team as we advance the clinical development of ADI-001 and rapidly develop a deep pipeline of "off-the-shelf" gamma delta T cell therapies," said Stewart Abbot, Chief Sci
MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Andrew Sinclair, Ph.D., to its board of directors. Dr. Sinclair will replace Erez Chimovits, who will step down from the Board of Directors. “Abingworth was a significant investor in our recent successful $152 million financing and we are extremely pleased to welcome Andrew, a highly-respected healthcare investor, to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio, Inc. “Andrew’s significan
Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate upda
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering under "Presentations & Events" in the investors section of the Company's website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To
ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T cell therapy Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome) Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved
ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high-grade aggressive NHL, as of December 5, 2022 data-cut date 100% ORR and CR rate in 5/5 anti-CD19 autologous chimeric antigen receptor T cells (CAR-T) relapsed large B-cell lymphoma (LBCL) patients 86% CR rate in LBCL patients across dose level three (DL3) and above (75% CR rate in LBCL patients across all dose levels) Both dose level 2 (DL2) and DL3 demonstrated a six-month CR rate of 33%; Patient follow up continues in dose level 4 (DL4) to assess six-month durability Circulating ADI-001 cells
Event to be webcast on Sunday, December 11, 2022 at 9:00 a.m. EST Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST to discuss the most recent data-cut from its ongoing Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL. The event will feature Sattva Neelapu, M.D., Professor in the Department of Lymphoma-Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, alongside
ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin's Lymphoma (NHL), as of May 31, 2022 data-cut date 80% ORR and CR rate at dose levels 2 and 3 combined 100% ORR and CR rate in three anti-CD19 CAR-T relapsed patients 50% of evaluable patients with at least six months follow-up remain cancer free Dose-related increase of ADI-001 exposure observed in blood Company expects to identify recommended Phase 2 dose in second half of 2022 and initiate at least one potentially pivotal study in first half of 2023 Company to host webcast today at 1:30pm PT / 4:30pm ET
Complete and near complete responses observed with ADI-001 starting at lowest dose level in Phase 1 study for the treatment of B-cell Non-Hodgkin's Lymphoma (ORR=75%, CR=50%)No ADI-001-related serious adverse events, including GvHD, neurotoxicity or high-grade CRS have been reported to dateEvidence of in vivo expansion and circulating pharmacodynamic biomarkers consistent with ADI-001 activationFavorable safety and clinical activity reinforces the potential of Adicet's first-in-class allogeneic, off-the-shelf gamma delta CAR T cell platformCompany to hold webcast today at 5:30am PT / 8:30am ET MENLO PARK, Calif. and BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (NASDAQ:ACET),
ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data Event to be webcast on December 6, 2021 at 8:30 a.m. EST MENLO PARK, Calif. and BOSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (NASDAQ:ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company will host a webcast presentation on Monday, December 6, 2021 at 8:30 AM EST to discuss interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet's investigational first-in-class allogeneic gamma delta CAR T cell